Chemistry:Lirilumab

From HandWiki
Revision as of 01:32, 27 June 2023 by JStaso (talk | contribs) (change)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Short description: Monoclonal antibody
Lirilumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetKIR2DL1/2/3
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6452H9918N1698O2030S46
Molar mass145228.93 g·mol−1

Lirilumab (INN) is a human monoclonal antibody designed for the treatment of cancer.[1][2] It binds to KIR2DL1/2L3.[3]

This drug was developed by Innate Pharma and is licensed to Bristol-Myers Squibb.

Clinical trials

A phase 2 clinical trial for acute myeloid leukemia (AML)[4] was terminated early ("failed") in 2017.[5]

It was registered for a trial for squamous cell carcinoma of the head and neck (SCCHN),[6] but it may be abandoned.[7]

(As of November 2017) nine clinical trials of lirilumab are registered as active.[8]

References

  1. ↑ World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107". WHO Drug Information 26 (2). https://www.who.int/medicines/publications/druginformation/innlists/Final_PL107.pdf. 
  2. ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Lirilumab, American Medical Association.
  3. ↑ "Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells". Blood 114 (13): 2667–77. September 2009. doi:10.1182/blood-2009-02-206532. PMID 19553639. 
  4. ↑ Clinical trial number NCT01687387 for "Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR)" at ClinicalTrials.gov
  5. ↑ Innate Pharma Leukemia Candidate Lirilumab Fails Phase II Trial. Feb 2017
  6. ↑ Clinical trial number NCT03341936 for "Adjuvant Nivolumab and Lirilumab in Patients With Relapsed, Resectable Squamous Cell Carcinoma of the Head and Neck " at ClinicalTrials.gov
  7. ↑ Bad news for Innate Pharma as BMS-backed drug stumbles nov 2017
  8. ↑ lirilumab trials




Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Lirilumab&oldid=2985511"